grade
pharmaceutical primary standard
API family
piperacillin
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
SMILES string
S1[C@H]2N([C@H](C1(C)C)C(=O)O)C(=O)[C@H]2NC(=O)[C@H](NC(=O)N4CCN(C(=O)C4=O)CC)c3ccccc3.O
InChI
1S/C23H27N5O7S.H2O/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);1H2/t13-,14-,15+,20-;/m1./s1
InChI key
NBXPLBPWMYNZTC-IDYPWDAWSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Piperacillin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
hcodes
signalword
Warning
Hazard Classifications
Aquatic Chronic 3 - Skin Sens. 1B
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
P1890000: + P1890000-1EA:
jan
Brian D VanScoy et al.
Antimicrobial agents and chemotherapy, 58(10), 6024-6031 (2014-07-30)
It is important to understand the relationship between antibiotic exposure and the selection of drug resistance in the context of therapy exposure. We sought to identify the ceftolozane-tazobactam exposure necessary to prevent the amplification of drug-resistant bacterial subpopulations in a
Sangil Jeon et al.
Antimicrobial agents and chemotherapy, 58(7), 3744-3751 (2014-04-23)
Piperacillin in combination with tazobactam, a β-lactamase inhibitor, is a commonly used intravenous antibiotic for the empirical treatment of infection in intensive care patients, including burn patients. The purpose of this study was to develop a population pharmacokinetic (PK) model
Ashley W Sturm et al.
Pharmacotherapy, 34(1), 28-35 (2013-07-19)
To evaluate the steady-state pharmacokinetic and pharmacodynamic parameters of piperacillin in morbidly obese, surgical intensive care patients. Open-label single-center prospective study. Level I trauma center and university-affiliated teaching institution. Nine morbidly obese (body mass index [BMI] 40.0 kg/m² or higher)
Raquel Cavalcanti Dantas et al.
Journal of medical microbiology, 63(Pt 12), 1679-1687 (2014-09-28)
The rates of multidrug-resistant, extensively drug-resistant and pandrug-resistant isolates amongst non-fermenting Gram-negative bacilli, particularly Pseudomonas aeruginosa, have risen worldwide. The clinical consequence of resistance and the impact of adverse treatment on the outcome of patients with P. aeruginosa bacteraemia remain
Imen Mokdad-Bzeouich et al.
The Journal of antibiotics, 68(3), 148-152 (2014-09-25)
In this particular study, the antibacterial activity of esculin and oligomer fractions was assessed. MIC values of esculin and its oligomer fractions as well as of some antibiotics against Gram-positive and Gram-negative strains and against Escherichia coli multiresistant variants were
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）